ANUM FAYYAZ MD
Prescription History 1790205821
Internal Medicine - Infectious Disease in Louisville, KY

NPI Status: Active since June 20, 2017

Contact Information

550 S JACKSON ST FL 2
LOUISVILLE, KY
ZIP 40202
Phone: (502) 561-8844

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ANUM FAYYAZ MD, an active Infectious Disease specialist practicing in Louisville, KY. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 29 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 16 claims alone.

Medication Index

No matching medications currently found on file.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 16.0
Days Supply 425
KY State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills87.6
Peer Average Days Supply2,118
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.2% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $355.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.37

State Avg Cost Per Claim

$49.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
KY State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills80.4
Peer Average Days Supply2,411
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.7% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,970.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,185.67

State Avg Cost Per Claim

$3,874.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ANUM FAYYAZ MD provides transparency into local medical care patterns within Louisville, KY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.